Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess safety, efficacy, and treatment retention following
extended treatment with OX219, a higher-bioavailability buprenorphine/naloxone (BNX)
sublingual tablet formulation in opioid-dependent patients who completed 1 of 2 primary
efficacy and safety studies of OX219.
Phase:
Phase 4
Details
Lead Sponsor:
Orexo AB
Collaborator:
Worldwide Clinical Trials
Treatments:
Analgesics, Opioid Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone